<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:03:43Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10947291" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10947291</identifier>
        <datestamp>2024-03-19</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="dme15032" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Diabet Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Diabet Med</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1464-5491</journal-id>
              <journal-id journal-id-type="publisher-id">DME</journal-id>
              <journal-title-group>
                <journal-title>Diabetic Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0742-3071</issn>
              <issn pub-type="epub">1464-5491</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10947291</article-id>
              <article-id pub-id-type="pmcid">PMC10947291</article-id>
              <article-id pub-id-type="pmc-uid">10947291</article-id>
              <article-id pub-id-type="pmid">36537852</article-id>
              <article-id pub-id-type="pmid">36537852</article-id>
              <article-id pub-id-type="doi">10.1111/dme.15032</article-id>
              <article-id pub-id-type="publisher-id">DME15032</article-id>
              <article-id pub-id-type="other">DME-2022-00531.R1</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research: Complications</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research: Complications</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Retinopathy prevalence, incidence and trajectories in type 2 diabetes: The Fremantle diabetes study phase <styled-content style="fixed-case" toggle="no">II</styled-content>
</article-title>
                <alt-title alt-title-type="left-running-head">Drinkwater et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="dme15032-cr-0001" contrib-type="author">
                  <name>
                    <surname>Drinkwater</surname>
                    <given-names>Jocelyn J.</given-names>
                  </name>
                  <xref rid="dme15032-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="dme15032-cr-0002" contrib-type="author">
                  <name>
                    <surname>Davis</surname>
                    <given-names>Timothy M. E.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0749-7411</contrib-id>
                  <xref rid="dme15032-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="dme15032-cr-0003" contrib-type="author">
                  <name>
                    <surname>Turner</surname>
                    <given-names>Angus W.</given-names>
                  </name>
                  <xref rid="dme15032-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="dme15032-cr-0004" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Davis</surname>
                    <given-names>Wendy A.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5709-8235</contrib-id>
                  <xref rid="dme15032-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>wendy.davis@uwa.edu.au</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="dme15032-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Medical School</named-content>
                <institution>The University of Western Australia, Fremantle Hospital</institution>
                <city>Fremantle</city>
                <named-content content-type="country-part">Western Australia</named-content>
                <country country="AU">Australia</country>
              </aff>
              <aff id="dme15032-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Centre for Ophthalmology and Visual Science (Incorporating Lions Eye Institute)</named-content>
                <institution>The University of Western Australia</institution>
                <city>Nedlands</city>
                <named-content content-type="country-part">Western Australia</named-content>
                <country country="AU">Australia</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Wendy A. Davis, Medical School, University of Western Australia, Fremantle Hospital, P. O. Box 480, Fremantle, WA 6959, Australia.<break/>
Email: <email>wendy.davis@uwa.edu.au</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>30</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <volume>40</volume>
              <issue seq="160">4</issue>
              <issue-id pub-id-type="doi">10.1111/dme.v40.4</issue-id>
              <elocation-id>e15032</elocation-id>
              <history>
                <date date-type="rev-recd">
                  <day>15</day>
                  <month>11</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>18</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>15</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--Diabetic Medicine &#x000a9; 2023 Diabetes UK-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Diabetic Medicine</italic> published by John Wiley &amp; Sons Ltd on behalf of Diabetes UK.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:DME-40-0.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="dme15032-sec-0001">
                  <title>Aims</title>
                  <p>To determine diabetic retinopathy (DR) prevalence, incidence, and whether distinct trajectories are associated with DR‐complicating Type 2 diabetes.</p>
                </sec>
                <sec id="dme15032-sec-0002">
                  <title>Methods</title>
                  <p>Retinal photographs from Fremantle Diabetes Study Phase II (FDS2) participants with Type 2 diabetes recruited in 2008–2011 and who attended biennial assessments for up to 6 years were graded as no DR, mild non‐proliferative DR (NPDR), moderate NPDR or severe NPDR/proliferative DR. Baseline DR prevalence, and the cumulative incidence of moderate NPDR or worse in those without DR at baseline, were calculated. Group‐based DR trajectory modelling was performed. Logistic regression determined independent associates of incident moderate NPDR or worse and trajectory group membership.</p>
                </sec>
                <sec id="dme15032-sec-0003">
                  <title>Results</title>
                  <p>Of 1521 participants (mean age 65.6 years, 52.1% males, median diabetes duration 9.0 years; 98% of all FDS2 participants with Type 2 diabetes) with gradable baseline photographs, 563 (37.0%) had DR. During a median 6.1 years of follow‐up, 23 (3.2%) without baseline DR developed at least moderate NPDR (crude incidence 6.1/1000 person‐years) with HbA<sub>1c</sub> the sole independent predictor (odds ratio [95% CI]: 1.62 [1.30–2.02] per 1% [11 mmol/mol] increase). Trajectory analysis showed two distinct groups, those with baseline/persistent DR (20%) and those remaining DR free (80%). Longer diabetes duration, insulin use, higher mean HbA<sub>1c</sub>, higher mean systolic blood pressure and higher mean urinary albumin: creatinine ratio all increased the odds (<italic toggle="no">p</italic> ≤ 0.014) of being in the persistent DR trajectory group.</p>
                </sec>
                <sec id="dme15032-sec-0004">
                  <title>Conclusions</title>
                  <p>The low incidence of at least moderate NPDR reflects the trajectory analysis. The currently recommended biennial retinal screening frequency for individuals without DR could potentially be extended.</p>
                </sec>
              </abstract>
              <abstract abstract-type="graphical">
                <p>
                  <boxed-text position="anchor" content-type="graphic" id="dme15032-blkfxd-1001">
                    <graphic xlink:href="DME-40-0-g003.jpg" position="anchor" id="jats-graphic-1"/>
                  </boxed-text>
                </p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="dme15032-kwd-0001">diabetic retinopathy</kwd>
                <kwd id="dme15032-kwd-0002">incidence</kwd>
                <kwd id="dme15032-kwd-0003">prevalence</kwd>
                <kwd id="dme15032-kwd-0004">trajectory analysis</kwd>
                <kwd id="dme15032-kwd-0005">type 2 diabetes</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>Medical Research Future Fund</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Health and Medical Research Council
</institution>
                      <institution-id institution-id-type="doi">10.13039/501100000925</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="3"/>
                <table-count count="3"/>
                <page-count count="10"/>
                <word-count count="4812"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>April 2023</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.9 mode:remove_FC converted:18.03.2024</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="DME15032-cit-2001"><string-name><surname>Drinkwater</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Davis</surname><given-names>TME</given-names></string-name>, <string-name><surname>Turner</surname><given-names>AW</given-names></string-name>, <string-name><surname>Davis</surname><given-names>WA</given-names></string-name>. <article-title>Retinopathy prevalence, incidence and trajectories in type 2 diabetes: The Fremantle diabetes study phase <styled-content style="fixed-case" toggle="no">II</styled-content>
</article-title>. <source>Diabet Med</source>. <year>2023</year>;<volume>40</volume>:<elocation-id>e15032</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/dme.15032</pub-id><pub-id pub-id-type="pmid">36537852</pub-id></mixed-citation>
              </p>
            </notes>
          </front>
          <body id="dme15032-body-0001">
            <p>
              <boxed-text position="anchor" content-type="box" id="dme15032-blkfxd-0001">
                <caption>
                  <title>Novelty statement</title>
                </caption>
                <sec id="dme15032-sec-0007">
                  <title>What's new</title>
                  <p>
                    <list list-type="bullet" id="dme15032-list-0001">
                      <list-item id="dme15032-li-0001">
                        <p>Whether the incidence of diabetic retinopathy (DR) complicating type 2 diabetes is decreasing is uncertain.</p>
                      </list-item>
                      <list-item id="dme15032-li-0002">
                        <p>In the community‐based longitudinal Fremantle Diabetes Study Phase II, there was a low incidence of DR (7.5% over 6 years), with few participants (0.4%) progressing to more severe DR.</p>
                      </list-item>
                      <list-item id="dme15032-li-0003">
                        <p>Participants without DR at baseline were likely to remain DR free over 6 years in trajectory analysis, supporting biennial rather than annual screening for retinopathy‐free people with type 2 diabetes.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
            </p>
            <sec id="dme15032-sec-0010">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>The incidence of most chronic vascular complications of diabetes has been decreasing in recent years in developed countries,<xref rid="dme15032-bib-0001" ref-type="bibr"><sup>1</sup></xref> likely reflecting earlier diabetes diagnosis and improved clinical management.<xref rid="dme15032-bib-0002" ref-type="bibr"><sup>2</sup></xref> Diabetic retinopathy (DR) is a common microvascular complication and a leading cause of visual impairment and blindness globally.<xref rid="dme15032-bib-0003" ref-type="bibr"><sup>3</sup></xref> Current evidence as to whether DR incidence is also decreasing is inconclusive.<xref rid="dme15032-bib-0001" ref-type="bibr"><sup>1</sup></xref> The Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) in the 1980 s showed that 97% of people with young‐onset insulin‐treated diabetes had developed retinopathy 20 years after diagnosis and that there was a high incidence of DR in those with older‐onset diabetes.<xref rid="dme15032-bib-0004" ref-type="bibr"><sup>4</sup></xref> These observations suggested a substantial lifetime DR risk but this may no longer apply given temporal trends in other complications. A recent review showed that the incidence of DR in people with Type 2 diabetes was lower in studies conducted after versus before 2000,<xref rid="dme15032-bib-0005" ref-type="bibr"><sup>5</sup></xref> and a UK study showed a significant decrease in the incidence of DR between 2013 and 2016.<xref rid="dme15032-bib-0006" ref-type="bibr"><sup>6</sup></xref> Furthermore, the global prevalence of DR appears to have decreased from 34.6% in a pooled analysis of studies conducted between 1980 and 2008<xref rid="dme15032-bib-0007" ref-type="bibr"><sup>7</sup></xref> to 22.2% in a more recent analysis in which studies up to 2020 were included.<xref rid="dme15032-bib-0008" ref-type="bibr"><sup>8</sup></xref> Although suggestive, these trends may be influenced by temporal changes in DR ascertainment and the accuracy and coverage of administrative datasets.</p>
              <p>Since DR is typically asymptomatic until late in the disease process, screening programmes are vital as they prevent vision loss and are cost‐effective.<xref rid="dme15032-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="dme15032-bib-0010" ref-type="bibr"><sup>10</sup></xref> In line with the likely decreasing prevalence of DR, recent publications have questioned whether the interval between DR screening visits could be lengthened to reduce costs without compromising outcomes,<xref rid="dme15032-bib-0011" ref-type="bibr"><sup>11</sup></xref> especially as most DR treatment is for proliferative disease or macular oedema. This suggestion is supported by some studies showing that the progression of DR is often slow, especially with shorter diabetes duration.<xref rid="dme15032-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="dme15032-bib-0011" ref-type="bibr"><sup>11</sup></xref> Indeed, personalized DR screening has been suggested, and an algorithm developed and validated by Icelandic researchers with those at low risk requiring screening only every 5 years.<xref rid="dme15032-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="dme15032-bib-0013" ref-type="bibr"><sup>13</sup></xref> There are, however, few contemporary community‐based studies assessing the incidence and progression of DR which would allow screening programmes to be developed on an appropriate evidence base.<xref rid="dme15032-bib-0014" ref-type="bibr"><sup>14</sup></xref>
</p>
              <p>The aim of the present study was, therefore, to ascertain DR prevalence and the incidence of moderate non‐proliferative DR (NPDR) or worse in well‐characterised community‐based people with Type 2 diabetes, and to determine whether there are sub‐groups with distinct DR trajectories whose characteristics could be used in the development of novel screening programmes.</p>
            </sec>
            <sec sec-type="methods" id="dme15032-sec-0011">
              <label>2</label>
              <title>METHODS</title>
              <sec id="dme15032-sec-0012">
                <label>2.1</label>
                <title>Patients and approvals</title>
                <p>Data from participants in the longitudinal observational Fremantle Diabetes Study Phase II (FDS2) were used.<xref rid="dme15032-bib-0015" ref-type="bibr"><sup>15</sup></xref> In brief, 1551 people with clinically diagnosed Type 2 diabetes were recruited from a postcode‐defined urban Australian population of approximately 150,000 between 2008 and 2011. All participants underwent comprehensive baseline and then biennial face‐to‐face assessments including an interview, questionnaires, a physical assessment and fasting biochemical tests. Each biennial assessment included single‐field, 45° retinal photographs of each eye taken using a Canon CR‐DGi Non‐Mydriatic Retinal Camera. If required, pupils were dilated using 0.5% tropicamide drops. The South Metropolitan Area Health Service Human Research Ethics Committee approved FDS2 and written informed consent was obtained from each participant. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki.</p>
              </sec>
              <sec id="dme15032-sec-0013">
                <label>2.2</label>
                <title>Retinopathy assessment</title>
                <p>Diabetic retinopathy was assessed according to the modified Airlie House Classification system for the Early Treatment Diabetic Retinopathy Study.<xref rid="dme15032-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="dme15032-bib-0017" ref-type="bibr"><sup>17</sup></xref> Baseline fundus photographs were assessed by a single external grader accredited by the Centre for Eye Research Australia, University of Melbourne, who was blinded to other participant data. Severity was classified as none, mild non‐proliferative diabetic retinopathy (NPDR), moderate NPDR, severe NPDR or worse.<xref rid="dme15032-bib-0018" ref-type="bibr"><sup>18</sup></xref> Level 10 was classified as no DR, levels 11–31 as mild NPDR, levels 41 and 84 as moderate NPDR, and levels 51–80 and 86 as severe NPDR or worse. For participants who did not have fundus photography or whose photographs were ungradable, further information regarding DR status was sought from hospital records and/or attending optometrists/ophthalmologists. Participants without information on DR status at baseline were excluded from the analysis.</p>
                <p>As the original grader was unavailable, follow‐up fundus photographs were first assessed independently by an experienced ophthalmologist under the same system used for the baseline images. A second ophthalmologist (AT) graded all photographs assessed as showing DR by the first, and he also graded a randomly‐selected sample of the remaining images. In discrepant cases, a consensus grading was obtained in consultation with a diabetologist with experience in DR (TMED). The worse eye from each assessment was used in the analysis.</p>
              </sec>
              <sec id="dme15032-sec-0014">
                <label>2.3</label>
                <title>Statistical analysis</title>
                <p>Statistical analyses were conducted using the computer package IBM SPSS for Windows (Version 25.0. IBM Corp) and Stata (Version 15.1, Stat Corp.). Data are presented as proportions, mean ± SD, geometric mean (SD range) or median [interquartile range]. For independent samples, two‐way comparisons for categorical variables were by Fisher's exact test, for normally or log‐normally distributed continuous variables by independent sample <italic toggle="yes">t</italic>‐test, and for variables not conforming to normal or log‐normal distribution by Mann–Whitney <italic toggle="yes">U</italic>‐test. A two‐tailed significance level of <italic toggle="yes">p</italic> &lt; 0.05 was used throughout.</p>
                <p>Baseline DR prevalence and the cumulative incidence of at least moderate NPDR in those without DR at baseline were calculated. Group‐based trajectory modelling, which employs finite mixture modelling to approximate unknown distributions of trajectories across a study population, identified whether distinct trajectories are associated with DR status (no DR or any DR). Logistic models were used to estimate trajectories of DR over 6 years in those participants with DR status available for ≥2 study visits. This was implemented using the procedure ‘traj’ in Stata (Version 15.1, Stat Corp).<xref rid="dme15032-bib-0019" ref-type="bibr"><sup>19</sup></xref> To assist model selection, the Bayesian Information Criterion (BIC) was utilised to determine the optimum number of groups and their functional form (linear, quadratic or cubic).<xref rid="dme15032-bib-0020" ref-type="bibr"><sup>20</sup></xref> Other selection criteria included: (i) adequate numbers of subjects in each group, (ii) distinct trajectories (non‐overlapping confidence intervals), (iii) acceptably narrow confidence intervals, (iv) average posterior probabilities of group membership &gt;0.70, (v) odds of correct classification based on posterior probabilities of group membership &gt;5 and (vi) close correspondence between group estimated probability and the proportion of participants classified to that group according to the maximum posterior probability assignment rule.</p>
                <p>When comparing differences between trajectory groups, the updated mean (the average of values at each assessment) of pertinent clinical values including HbA<sub>1c</sub>, supine systolic blood pressure and urinary albumin: creatinine ratio (uACR) were used. Backward conditional logistic regression models determined the independent associates of the different trajectory groups and incident moderate NPDR or worse in those with no DR at baseline and at least one follow‐up visit. Variables with <italic toggle="yes">p</italic> &lt; 0.20 in the bivariable analyses were considered for model entry.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="dme15032-sec-0015">
              <label>3</label>
              <title>RESULTS</title>
              <sec id="dme15032-sec-0016">
                <label>3.1</label>
                <title>Participant disposition and baseline characteristics</title>
                <p>Baseline DR status was available for 1521 (98%) of FDS2 participants with Type 2 diabetes. Their mean ± SD age was 65.6 ± 11.5 years, 52% were males, and their median (inter‐quartile range [IQR]) diabetes duration was 9.0 [2.9–15.8] years. Their median [IQR] HbA<sub>1c</sub> was 6.8[6.2–7.7]% (51[44–61] mmol/mol) and mean supine systolic blood pressure was 146 ± 22 mmHg. A participant flow diagram is shown in Figure <xref rid="dme15032-fig-0001" ref-type="fig">1</xref>. The baseline DR prevalence was 37%, most (79%) of which was mild. Of 958 (63%) without DR at baseline, the 726 (76%) who had DR status ascertained as part of at least one follow‐up visit were included in the analysis of DR incidence.</p>
                <fig position="float" fig-type="FIGURE" id="dme15032-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Consort diagram showing participants included in analysis.</p>
                  </caption>
                  <graphic xlink:href="DME-40-0-g001" position="anchor" id="jats-graphic-3"/>
                </fig>
              </sec>
              <sec id="dme15032-sec-0017">
                <label>3.2</label>
                <title>Incident diabetic retinopathy</title>
                <p>Of the eligible 726 participants without DR at baseline, 54 (7.5%) developed DR during a median of 6.0 years of follow‐up (crude incidence 14.5/1000 person‐years). Twenty‐three (3.2%) developed at least moderate NPDR during a median of 6.1 years of follow‐up (crude incidence 6.1/1000 person‐years). Of these, only 3 (0.4%) developed severe NPDR or PDR during follow‐up. Bivariable analysis comparing baseline characteristics of those who developed at least moderate NPDR during follow‐up to those who did not are shown in Table <xref rid="dme15032-tbl-0001" ref-type="table">1</xref>. Higher fasting serum glucose, HbA<sub>1c</sub>, and uACR were associated with the development of at least moderate NPDR. In logistic regression modelling, HbA<sub>1c</sub> at baseline was the sole independent predictor (odds ratio (95% CI): 1.62 (1.30–2.02) per 1% (11 mmol/mol) increase) of new moderate NPDR or worse during follow‐up.</p>
                <table-wrap position="float" id="dme15032-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Bivariable statistics comparing those who developed at least moderate non‐proliferative diabetic retinopathy (NPDR) during follow‐up to those who did not, in participants with type 2 diabetes who had no diabetic retinopathy at baseline and had at least one follow‐up visit</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Variables at baseline</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">No moderate NPDR or worse during follow‐up</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">At least moderate NPDR during follow‐up</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">703 (97)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">23 (3.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age at FDS entry (years)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64.5 ± 10.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">66.1 ± 11.1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.507</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sex (% male)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">350 (50)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10 (44)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.673</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Ethnic background (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.985</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Anglo‐Celt</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">409 (58)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15 (65)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Southern European</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64 (9.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other European</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">47 (6.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Asian</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29 (4.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Indigenous Australian</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (3.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mixed/other</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">127 (18)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Not fluent in English (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">49 (7.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.673</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Education beyond primary level (%)<sup>a</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">633 (91)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">23 (100)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.250</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Currently married/de facto (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">460 (65)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (57)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.381</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Private health insurance (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">456 (65)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (61)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.665</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Duration of diabetes (years at study entry)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5.0 [1.4–12.0]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.0 [5.0–15.1]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.102</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">On insulin (with or without other OGA as %)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">83 (12)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (26)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.052</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Fasting glucose (mmol/L)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.0 [6.1–8.3]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.2 [6.7–9.9]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.005</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.6 [6.1–7.4]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.7 [7.0–9.2]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HbA<sub>1c</sub> (mmol/mol)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">49 [43–57]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61 [53–77]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Self‐monitors blood glucose (%)<sup>c</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">601 (86)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18 (78)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.354</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31.2 ± 6.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">32.0 ± 5.5</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.520</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Obesity (% by waist circumference)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">488 (69)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19 (83)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.248</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Heart rate (bpm)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">68 ± 12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">69 ± 10</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.892</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Supine systolic blood pressure (mmHg)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">143 ± 20</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">147 ± 22</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.294</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Supine diastolic blood pressure (mmHg)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80 ± 12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80 ± 16</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.912</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Total cholesterol (mmol/L)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.4 ± 1.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.8 ± 1.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.066</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HDL‐cholesterol (mmol/L)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.2 ± 0.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.3 ± 0.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.722</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Serum triglycerides (mmol/L)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.9–2.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.7 (1.1–2.9)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.134</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Urinary albumin: creatinine (mg/mmol)<sup>d</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.5 (0.8–7.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5.2 (1.3–21.0)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.004</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">eGFR (CKD‐EPI) categories (%)<sup>e</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.976</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥90 ml/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">296 (42)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9 (39)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">60–89 ml/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">330 (47)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (52)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">45–59 ml/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">42 (6.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&lt;45 ml/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31 (4.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any ischaemic heart disease (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">169 (24)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9 (39)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.135</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Cerebrovascular disease (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">37 (5.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.128</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Peripheral arterial disease (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">130 (19)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.999</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Peripheral sensory neuropathy (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">386 (55)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (57)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.999</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any depression (%)<sup>f</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">66 (9.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.472</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Alcohol (standard drinks/day)<sup>g</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.1 [0–1.2]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.1 [0–0.3]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.232</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Current smoker (%)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">53 (7.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">≤5 (22)<xref rid="dme15032-note-0002" ref-type="table-fn">*</xref>
</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.691</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="dme15032-ntgp-0001">
                    <fn id="dme15032-note-0001">
                      <p><italic toggle="yes">Note</italic>: Data are presented as number (percentage), mean ± standard deviation, geometric mean (standard deviation range) or median [inter‐quartile range]. Missing data: <sup>a</sup>
<italic toggle="yes">n</italic> = 8 (1.1%); <sup>b</sup>
<italic toggle="yes">n</italic> = 1 (0.1%); <sup>c</sup>
<italic toggle="yes">n</italic> = 5 (0.7%); <sup>d</sup>
<italic toggle="yes">n</italic> = 2 (0.3%); <sup>e</sup>
<italic toggle="yes">n</italic> = 4 (0.6%); <sup>f</sup>
<italic toggle="yes">n</italic> = 31 (4.3%); <sup>g</sup>
<italic toggle="yes">n</italic> = 28 (3.9%).</p>
                    </fn>
                    <fn id="dme15032-note-0002">
                      <label>*</label>
                      <p>Exact numbers withheld to ensure participant privacy and confidentiality.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="dme15032-sec-0018">
                <label>3.3</label>
                <title>Trajectory analysis</title>
                <p>Trajectory analysis included 1115 participants (72% of the Type 2 diabetes cohort) who had DR assessed at ≥2 study visits. At entry, these participants had a mean ± SD age of 64.6 ± 10.9 years, 54% were males and their median [IQR] diabetes duration was 8.0 [2.0–15.0] years. There were 313 with mild NPDR at baseline and at least one follow‐up visit, of whom 60 (14%) progressed to at least moderate NPDR. The best model (with the lowest BIC) identified two groups, those with baseline and persistent DR (Persistent DR group), and those without DR at baseline who remained DR free (No DR group; Table <xref rid="dme15032-supitem-0001" ref-type="supplementary-material">1</xref>). The No DR group was the largest (<italic toggle="yes">n</italic> = 893 [80%]). Both groups had a generally flat cubic trajectory. Figure <xref rid="dme15032-fig-0002" ref-type="fig">2</xref> illustrates the two trajectories and their narrow 95% confidence intervals. Although the BIC was similar for a three‐group model, there were inadequate numbers (&lt;10%) in two of the three groups.</p>
                <fig position="float" fig-type="FIGURE" id="dme15032-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>The results from the trajectory analysis show two distinct retinopathy groups, the Persistent DR group (above) and no DR group (below) with 95% confidence intervals (dashed grey lines) for both.</p>
                  </caption>
                  <graphic xlink:href="DME-40-0-g002" position="anchor" id="jats-graphic-5"/>
                </fig>
                <p>There was close agreement between observed and predicted DR status (Table <xref rid="dme15032-supitem-0001" ref-type="supplementary-material">S2</xref>). The average posterior probabilities for the trajectory groups were 0.97 (No DR) and 0.96 (Persistent DR), both exceeding the recommended 0.7 cut‐off. The odds of correct classification based on the posterior probabilities of group membership were &gt;5 for both groups (Table <xref rid="dme15032-supitem-0001" ref-type="supplementary-material">S3</xref>). Each group's estimated probability corresponded closely to the proportion of participants allocated to that group according to the maximum posterior probability assignment rule (Table <xref rid="dme15032-supitem-0001" ref-type="supplementary-material">S4</xref>). Group‐based trajectory modelling describes the progression of a phenomenon (DR) over time and identifies variations in its progression between groups of individuals.<xref rid="dme15032-bib-0019" ref-type="bibr"><sup>19</sup></xref> However, this is a generalisation; some participants in the No DR group developed DR and some in the Persistent DR group improved (Figure <xref rid="dme15032-fig-0002" ref-type="fig">2</xref> and Supplemental Table <xref rid="dme15032-supitem-0001" ref-type="supplementary-material">S2</xref>).</p>
              </sec>
              <sec id="dme15032-sec-0019">
                <label>3.4</label>
                <title>Trajectory group characteristics</title>
                <p>The bivariable analysis of the characteristics of the two trajectory groups is summarised in Table <xref rid="dme15032-tbl-0002" ref-type="table">2</xref>. Persistent DR group members were less likely to be of Anglo‐Celt ethnicity and to speak English fluently. They were more likely to be of Asian, Indigenous Australian or Southern European ethnicity, to have been insulin‐treated at baseline, and they had a higher baseline and updated mean HbA<sub>1c</sub>, uACR and systolic blood pressure, and a higher baseline heart rate. They were more likely to be obese (by waist circumference) and have cerebrovascular and peripheral arterial disease at baseline. Persistent DR group members were also more likely to have a lower baseline eGFR. In multiple logistic regression analysis, longer diabetes duration, insulin use, higher updated mean HbA<sub>1c</sub>, higher updated mean systolic blood pressure and higher updated mean uACR independently increased the odds of being in the Persistent DR trajectory group (<italic toggle="yes">p</italic> ≤ 0.014; Table <xref rid="dme15032-tbl-0003" ref-type="table">3</xref>). Those in the no DR group were more likely to have had DR assessed at all four study visits when compared to the Persistent DR group (57% and 43%, respectively, <italic toggle="yes">p</italic> &lt; 0.001).</p>
                <table-wrap position="float" id="dme15032-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Bivariable analysis showing differences between the two diabetic retinopathy trajectory groups</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="char" char="." span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Variables at baseline</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Group 1: no diabetic retinopathy group</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Group 2: persistent diabetic retinopathy group</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Number (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">893 (80)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">222 (20)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Age at FDS entry (years)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64.6 ± 10.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64.5 ± 11.5</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.911</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Sex (% male)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">474 (53)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">128 (58)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.229</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Ethnic background (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Anglo‐Celt</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">525 (59)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">106 (48)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Southern European</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">86 (9.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">38 (17)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Other European</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64 (7.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19 (8.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Asian</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">35 (3.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (5.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Indigenous Australian</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">35 (3.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17 (7.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mixed/other</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">148 (17)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29 (13)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Not fluent in English (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61 (6.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Education beyond primary level (%)<sup>a</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">808 (92)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">192 (88)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.067</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Currently married/de facto (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">589 (66)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">145 (65)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.874</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Private health insurance (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">575 (64)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">139 (63)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.640</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Duration of diabetes (years at study entry)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5.0 [1.7–12.1]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15.8 [11.0–20.3]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">On insulin (with or without other OGA as %)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">116 (13)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">110 (50)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Fasting glucose (mmol/L)<sup>c</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.0 [6.1–8.4]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.1 [6.6–10.3]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HbA<sub>1c</sub> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.7 [6.1–7.4]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.4 [6.8–8.8]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HbA<sub>1c</sub> (mmol/mol)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">50 [43–57]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">57 [51–73]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Self‐monitors blood glucose (%)<sup>d</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">755 (85)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">191 (87)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.668</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31.3 ± 6.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31.9 ± 5.5</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.182</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Obesity (% by waist circumference)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">768 (86)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">204 (92)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.013</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Heart rate (bpm) <sup>c</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">68 ± 12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">72 ± 13</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Supine systolic blood pressure (mmHg)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">144 ± 20</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">151 ± 23</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Supine diastolic blood pressure (mmHg)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80 ± 12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">82 ± 12</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.089</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Total cholesterol (mmol/L)<sup>e</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.4 ± 1.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.3 ± 1.1</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.398</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">HDL‐cholesterol (mmol/L)<sup>e</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.2 ± 0.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.2 ± 0.3</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.507</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Serum triglycerides (mmol/L)<sup>e</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.9–2.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.6 (0.9–2.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.274</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Urinary albumin: creatinine (mg/mmol)<sup>e</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.6 (0.8–8.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5.3 (1.1–25.2)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">eGFR (CKD‐EPI) categories (%)<sup>f</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.008</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥90 mL/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">370 (42)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">85 (39)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">60–89 mL/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">418 (47)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">93 (42)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">45–59 mL/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">63 (7.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20 (9.1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">&lt;45 mL/min/1.73 m<sup>2</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">38 (4.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22 (10)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any ischaemic heart disease (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">224 (25)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64 (29)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.266</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any cerebrovascular disease (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">48 (5.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">24 (11)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.006</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Peripheral arterial disease (%)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">158 (18)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">56 (25)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.013</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Peripheral sensory neuropathy (%)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">494 (55)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">138 (62)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.058</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Any depression (%)<sup>g</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">83 (9.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">30 (14)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.060</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Alcohol (standard drinks/day)<sup>h</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.1 [0–1.2]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.1 [0–1.3]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.126</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Smoking status (%)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="char" valign="top" rowspan="1" colspan="1">0.672</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Never</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">415 (47)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">98 (44)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Ex‐smoker</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">402 (45)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">102 (46)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Current smoker</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">75 (8.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22 (9.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" valign="top" rowspan="1">Other data</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Updated mean HbA<sub>1c</sub> (%)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.9 [6.3–7.6]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.7 [6.9–8.7]</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Updated mean urinary albumin: creatinine (mg/mmol)<sup>b</sup>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.1 (0.9–10.7)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.6 (1.6–36.6)</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Updated mean supine systolic blood pressure (mmHg)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">141 ± 16</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">148 ± 17</td>
                        <td align="char" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="dme15032-ntgp-0002">
                    <fn id="dme15032-note-0003">
                      <p><italic toggle="yes">Note</italic>: Data are presented as number (percentage), mean ± standard deviation, geometric mean (standard deviation range) or median [inter‐quartile range]. Missing data: <sup>a</sup>
<italic toggle="yes">n</italic> = 15 (1.3%); <sup>b</sup>
<italic toggle="yes">n</italic> = 1 (0.1%); <sup>c</sup>
<italic toggle="yes">n</italic> = 2 (0.2%); <sup>d</sup>
<italic toggle="yes">n</italic> = 10 (0.9%); <sup>e</sup>
<italic toggle="yes">n</italic> = 3 (0.3%); <sup>f</sup>
<italic toggle="yes">n</italic> = 6 (0.5%); <sup>g</sup>
<italic toggle="yes">n</italic> = 52 (4.7%); <sup>h</sup>
<italic toggle="yes">n</italic> = 44 (3.9%).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="dme15032-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Multiple logistic regression analysis showing the variables independently associated with being in the persistent DR trajectory group</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Odds ratio (95% confidence interval)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Diabetes duration at baseline (per 1‐year increase)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.12 (1.09–1.15)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">On insulin at baseline</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.52 (1.72–3.70)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Updated mean HbA<sub>1c</sub> (per 1% or 11 mmol/mol increase)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.50 (1.30–1.72)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Ln (updated mean urinary albumin: creatinine ratio)<xref rid="dme15032-note-0004" ref-type="table-fn"><sup>a</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.19 (1.04–1.36)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.009</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Updated mean supine systolic blood pressure (per 10 mmHg increase)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1.14 (1.03–1.28)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.014</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="dme15032-ntgp-0003">
                    <fn id="dme15032-note-0004">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>A 2.72‐fold increase in the updated mean urinary albumin: creatinine ratio corresponds to an increase of 1 in ln(updated mean urinary albumin: creatinine ratio).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="dme15032-sec-0020">
              <label>4</label>
              <title>DISCUSSION</title>
              <p>In our community‐based Australians with Type 2 diabetes, just over one‐third had DR at baseline and the incidence of moderate NPDR or worse in those without DR at baseline was low. Trajectory analysis showed little change in DR status during 6 years of follow‐up. This suggests that most people with Type 2 diabetes without DR are very likely to remain DR free. Hyperglycaemia, assessed from fasting serum glucose and/or HbA<sub>1c</sub>, was independently associated with both the incidence of moderate NPDR and Persistent DR trajectory group membership. Additionally, longer diabetes duration, hypertension and higher uACR were independently associated with being in the Persistent DR group. These findings have implications for clinical management.</p>
              <p>The prevalence of DR varies greatly between studies, from 5% to 40% in recent reports.<xref rid="dme15032-bib-0011" ref-type="bibr"><sup>11</sup></xref>, <xref rid="dme15032-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="dme15032-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="dme15032-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="dme15032-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="dme15032-bib-0024" ref-type="bibr"><sup>24</sup></xref> The global prevalence of DR has been estimated at 22%<xref rid="dme15032-bib-0008" ref-type="bibr"><sup>8</sup></xref> which is lower than the 37% prevalence in our study. The United Kingdom Prospective Diabetes Study (UKPDS) also had a 37% prevalence of any DR at baseline in newly diagnosed Type 2 diabetes<xref rid="dme15032-bib-0025" ref-type="bibr"><sup>25</sup></xref> and the baseline prevalence in the WESDR was similar at 39% in the older onset group not on insulin even if there was a higher 70% prevalence in the older onset insulin‐treated group.<xref rid="dme15032-bib-0004" ref-type="bibr"><sup>4</sup></xref> A more recent Saudi Arabian study using data from a chronic illness clinic found a 38% prevalence for any DR in people with Type 2 diabetes,<xref rid="dme15032-bib-0023" ref-type="bibr"><sup>23</sup></xref> similar to our results. In a 2018 Thai study,<xref rid="dme15032-bib-0024" ref-type="bibr"><sup>24</sup></xref> a 5% prevalence of DR in people with Type 2 diabetes was lower than in many other studies, likely reflecting the lack of data from university hospitals including tertiary medical centres.<xref rid="dme15032-bib-0024" ref-type="bibr"><sup>24</sup></xref>
</p>
              <p>Differences in study sampling methods and ascertainment of DR status could contribute to the large variations in reported DR prevalence. Lowering of the fasting serum glucose required for diabetes diagnosis in 1999 and greater diabetes awareness has led to earlier diabetes diagnosis and therefore earlier DR screening, which would very likely affect DR prevalence and incidence. Furthermore, emphasis on the importance of intensive cardiovascular, including glycaemic, management has resulted in better blood pressure and improved glucose levels which would lower DR prevalence.<xref rid="dme15032-bib-0006" ref-type="bibr"><sup>6</sup></xref> Notwithstanding these considerations, our DR prevalence is at the upper end of the range of published rates and shows that more than one in three Australians with Type 2 diabetes has DR.</p>
              <p>The incidence of DR also varies greatly between studies. A UK retrospective cohort analysis found that 46% of those with newly diagnosed Type 2 diabetes who were retinopathy‐free developed DR after 7 years.<xref rid="dme15032-bib-0022" ref-type="bibr"><sup>22</sup></xref> This study used the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) database and ascertained DR status using diagnosis codes,<xref rid="dme15032-bib-0022" ref-type="bibr"><sup>22</sup></xref> although the validity of the database is unclear, particularly regarding those without DR. Another UK population‐based study reported an 8.5% annual incidence of new DR in 2016 in those with Type 2 diabetes using electronic medical records.<xref rid="dme15032-bib-0006" ref-type="bibr"><sup>6</sup></xref> In a review of population‐based studies of Type 1 and/or Type 2 diabetes conducted after 2000, the annual incidence of DR ranged from 2.2% to 12.7%.<xref rid="dme15032-bib-0005" ref-type="bibr"><sup>5</sup></xref> Our study found that 7.5% of participants developed DR during a median of 6 years suggesting a rate below this range. In the WESDR there was a much higher incidence in the older onset cohort, with 47% of those on insulin and 34% of those not on insulin developing any DR over a four‐year period,<xref rid="dme15032-bib-0026" ref-type="bibr"><sup>26</sup></xref> whilst 22% of UKPDS participants developed DR over a six‐year period.<xref rid="dme15032-bib-0025" ref-type="bibr"><sup>25</sup></xref> Despite the FDS2 prevalence being similar to these older studies, our incidence rates were much lower which likely reflects more intensive contemporary risk factor management.</p>
              <p>Our novel trajectory analysis showed two distinct groups. The largest comprised those without DR who were likely to remain DR free over 6 years. This observation lends support to current Australian guidelines recommending biennial DR screening for those without risk factors<xref rid="dme15032-bib-0027" ref-type="bibr"><sup>27</sup></xref> but suggests that even longer intervals could be considered for low‐risk people with Type 2 diabetes. The Icelandic personalised DR risk equation has shown that screening intervals can be up to 60 months without compromising outcomes,<xref rid="dme15032-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="dme15032-bib-0013" ref-type="bibr"><sup>13</sup></xref> with biennial screening reduced by 23% and annual screening by 61% in the Netherlands validation cohort.<xref rid="dme15032-bib-0013" ref-type="bibr"><sup>13</sup></xref> Danish DR screening guidelines, updated in 2018, now recommend up to 48‐month intervals for those at lower risk and up to 24 months for those with moderate NPDR, depending on risk factors.<xref rid="dme15032-bib-0028" ref-type="bibr"><sup>28</sup></xref> Our trajectory analysis data and these European studies support lengthening Australian DR screening intervals to 48–60 months in those without DR and at low risk, specifically individuals with short‐duration, non‐insulin‐treated Type 2 diabetes without nephropathy and with adequate glycaemic and blood pressure control.</p>
              <p>As just 14% of our participants progressed from mild to moderate NPDR or worse during follow‐up, screening intervals in those with DR could potentially be extended beyond annual reviews. Those with DR were less likely to attend all follow‐up visits, but participants may have attended DR screening elsewhere as part of usual care. A recent publication found those at increased risk of DR progression undergoing 18‐month screening had greater adherence to screening than those with a 36‐month interval, but adherence rates were &gt; 90% in both groups.<xref rid="dme15032-bib-0029" ref-type="bibr"><sup>29</sup></xref> Nevertheless, a history of non‐adherence should not influence screening intervals.<xref rid="dme15032-bib-0028" ref-type="bibr"><sup>28</sup></xref>
</p>
              <p>More frequent DR screening can be tailored to individual risk factors. In the UK, a randomised controlled trial determined that individualised risk‐based screening at 6‐, 12‐ or 24‐month intervals were non‐inferior to the recommended annual screening.<xref rid="dme15032-bib-0030" ref-type="bibr"><sup>30</sup></xref> In an Australian context, Aboriginal or Torres Strait Islanders with diabetes who have longer duration disease, suboptimal glycaemia, hypertension, renal disease or dyslipidaemia are recommended to have annual screening.<xref rid="dme15032-bib-0027" ref-type="bibr"><sup>27</sup></xref> Those with DR are recommended for even more frequent reviews.<xref rid="dme15032-bib-0027" ref-type="bibr"><sup>27</sup></xref> Our study findings support these guidelines since the variables associated with the DR group in our trajectory analysis were longer diabetes duration, higher HbA<sub>1c</sub>, insulin use (which may reflect sustained hyperglycaemia), hypertension and uACR, all well‐known DR risk factors.<xref rid="dme15032-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="dme15032-bib-0007" ref-type="bibr"><sup>7</sup></xref>, <xref rid="dme15032-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="dme15032-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="dme15032-bib-0025" ref-type="bibr"><sup>25</sup></xref>
</p>
              <p>The strengths of this study include using novel trajectory analysis to examine temporal changes in DR, the representative community‐based sample and comprehensive face‐to‐face assessments. Limitations include the use of single‐field retinal images which may have underestimated the DR presence and/or severity, potentially biasing the results towards the null. There may be inter‐rater bias as different graders performed the baseline and follow‐up grading, despite using the same classification system. Additionally, we did not include macular oedema grading in our analyses.</p>
              <p>In conclusion, our novel trajectory analysis showed that FDS2 participants with Type 2 diabetes without DR were likely to remain DR‐free during 6 years of follow‐up. This was supported by a low incidence of at least moderate NPDR. Our results are in accord with current Australian DR screening guidelines but suggest that the screening interval in low‐risk people with Type 2 diabetes could be extended beyond the currently recommended two‐year period.</p>
            </sec>
            <sec id="dme15032-sec-0022">
              <title>FUNDING INFORMATION</title>
              <p>The FDS2 was funded by the National Health and Medical Research Council of Australia (project grants 513781 and 1042231). TMED is supported by a Medical Research Future Fund Practitioner Fellowship. These funding bodies had no involvement in the study design, data collection, analysis and interpretation of results or writing of this manuscript.</p>
            </sec>
            <sec sec-type="COI-statement" id="dme15032-sec-0023">
              <title>CONFLICT OF INTEREST</title>
              <p>None to declare.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="dme15032-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>
Table S1–S4
</p>
                </caption>
                <media xlink:href="DME-40-0-s001.docx"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="dme15032-sec-0021">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors wish to thank the Fremantle Diabetes Study Phase II staff, investigators and participants, the staff at the West Australian Data Linkage Branch and the Hospital Morbidity Data Collection. Open access publishing facilitated by The University of Western Australia, as part of the Wiley ‐ The University of Western Australia agreement via the Council of Australian University Librarians.</p>
            </ack>
            <sec sec-type="data-availability" id="dme15032-sec-0025">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>The datasets generated and analysed during the current study are not publicly available. However, anonymised data are available from the corresponding author upon reasonable request, excluding prevalent coronary heart disease and cerebrovascular disease. The latter were identified through health data linkage with permission from the Western Australian Department of Health and cannot be shared without approval.</p>
            </sec>
            <ref-list content-type="cited-references" id="dme15032-bibl-0001">
              <title>REFERENCES</title>
              <ref id="dme15032-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0001"><string-name><surname>Harding</surname><given-names>JL</given-names></string-name>, <string-name><surname>Pavkov</surname><given-names>ME</given-names></string-name>, <string-name><surname>Magliano</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>JE</given-names></string-name>, <string-name><surname>Gregg</surname><given-names>EW</given-names></string-name>. <article-title>Global trends in diabetes complications: a review of current evidence</article-title>. <source>Diabetologia</source>. <year>2019</year>;<volume>62</volume>:<fpage>3</fpage>‐<lpage>16</lpage>.<pub-id pub-id-type="pmid">30171279</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0002"><string-name><surname>Fang</surname><given-names>M</given-names></string-name>, <string-name><surname>Selvin</surname><given-names>E</given-names></string-name>. <article-title>Thirty‐year trends in complications in U.S. adults with newly diagnosed type 2 diabetes</article-title>. <source>Diabetes Care</source>. <year>2021</year>;<volume>44</volume>:<fpage>699</fpage>‐<lpage>706</lpage>.<pub-id pub-id-type="pmid">33419932</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0003"><string-name><surname>Flaxman</surname><given-names>SR</given-names></string-name>, <string-name><surname>Bourne</surname><given-names>RRA</given-names></string-name>, <string-name><surname>Resnikoff</surname><given-names>S</given-names></string-name>, et al. <article-title>Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta‐analysis</article-title>. <source>Lancet Glob Health</source>. <year>2017</year>;<volume>5</volume>:<fpage>e1221</fpage>‐<lpage>e1234</lpage>.<pub-id pub-id-type="pmid">29032195</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0004"><string-name><surname>Klein</surname><given-names>R</given-names></string-name>, <string-name><surname>Klein</surname><given-names>BE</given-names></string-name>, <string-name><surname>Moss</surname><given-names>SE</given-names></string-name>. <article-title>The Wisconsin epidemiological study of diabetic retinopathy: a review</article-title>. <source>Diabetes Metab Rev</source>. <year>1989</year>;<volume>5</volume>:<fpage>559</fpage>‐<lpage>570</lpage>.<pub-id pub-id-type="pmid">2689119</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0005"><string-name><surname>Sabanayagam</surname><given-names>C</given-names></string-name>, <string-name><surname>Banu</surname><given-names>R</given-names></string-name>, <string-name><surname>Chee</surname><given-names>ML</given-names></string-name>, et al. <article-title>Incidence and progression of diabetic retinopathy: a systematic review</article-title>. <source>Lancet Diabetes Endocrinol</source>. <year>2019</year>;<volume>7</volume>:<fpage>140</fpage>‐<lpage>149</lpage>.<pub-id pub-id-type="pmid">30005958</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0006"><string-name><surname>Scanlon</surname><given-names>PH</given-names></string-name>, <string-name><surname>Nevill</surname><given-names>CR</given-names></string-name>, <string-name><surname>Stratton</surname><given-names>IM</given-names></string-name>, et al. <article-title>Prevalence and incidence of diabetic retinopathy (DR) in the UK population of Gloucestershire</article-title>. <source>Acta Ophthalmol</source>. <year>2022</year>;<volume>100</volume>:<fpage>e560</fpage>‐<lpage>e570</lpage>.<pub-id pub-id-type="pmid">34180581</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0007"><string-name><surname>Yau</surname><given-names>JWY</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>SL</given-names></string-name>, <string-name><surname>Kawasaki</surname><given-names>R</given-names></string-name>, et al. <article-title>Global prevalence and major risk factors of diabetic retinopathy</article-title>. <source>Diabetes Care</source>. <year>2012</year>;<volume>35</volume>:<fpage>556</fpage>‐<lpage>564</lpage>.<pub-id pub-id-type="pmid">22301125</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0008"><string-name><surname>Teo</surname><given-names>ZL</given-names></string-name>, <string-name><surname>Tham</surname><given-names>Y‐C</given-names></string-name>, <string-name><surname>Yu</surname><given-names>M</given-names></string-name>, et al. <article-title>Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta‐analysis</article-title>. <source>Ophthalmology</source>. <year>2021</year>;<volume>128</volume>:<fpage>1580</fpage>‐<lpage>1591</lpage>.<pub-id pub-id-type="pmid">33940045</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0009"><string-name><surname>Rein</surname><given-names>DB</given-names></string-name>, <string-name><surname>Wittenborn</surname><given-names>JS</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, et al. <article-title>The cost‐effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy: cost‐effectiveness of diabetic retinopathy screening</article-title>. <source>Health Serv Res</source>. <year>2011</year>;<volume>46</volume>:<fpage>1534</fpage>‐<lpage>1561</lpage>.<pub-id pub-id-type="pmid">21492158</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0010"><string-name><surname>Rohan</surname><given-names>TE</given-names></string-name>, <string-name><surname>Frost</surname><given-names>CD</given-names></string-name>, <string-name><surname>Wald</surname><given-names>NJ</given-names></string-name>. <article-title>Prevention of blindness by screening for diabetic retinopathy: a quantitative assessment</article-title>. <source>BMJ</source>. <year>1989</year>;<volume>299</volume>:<fpage>1198</fpage>‐<lpage>1201</lpage>.<pub-id pub-id-type="pmid">2513049</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0011"><string-name><surname>Voigt</surname><given-names>M</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>S</given-names></string-name>, <string-name><surname>Lehmann</surname><given-names>T</given-names></string-name>, et al. <article-title>Prevalence and progression rate of diabetic retinopathy in type 2 diabetes patients in correlation with the duration of diabetes</article-title>. <source>Exp Clin Endocrinol Diabetes</source>. <year>2018</year>;<volume>126</volume>:<fpage>570</fpage>‐<lpage>576</lpage>.<pub-id pub-id-type="pmid">29183104</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0012"><string-name><surname>Aspelund</surname><given-names>T</given-names></string-name>, <string-name><surname>Þórisdóttir</surname><given-names>Ó</given-names></string-name>, <string-name><surname>Ólafsdottir</surname><given-names>E</given-names></string-name>, et al. <article-title>Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy</article-title>. <source>Diabetologia</source>. <year>2011</year>;<volume>54</volume>:<fpage>2525</fpage>‐<lpage>2532</lpage>.<pub-id pub-id-type="pmid">21792613</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0013"><string-name><surname>van der Heijden</surname><given-names>AAWA</given-names></string-name>, <string-name><surname>Walraven</surname><given-names>I</given-names></string-name>, <string-name><surname>Van't Riet</surname><given-names>E</given-names></string-name>, et al. <article-title>Validation of a model to estimate personalised screening frequency to monitor diabetic retinopathy</article-title>. <source>Diabetologia</source>. <year>2014</year>;<volume>57</volume>:<fpage>1332</fpage>‐<lpage>1338</lpage>.<pub-id pub-id-type="pmid">24763851</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0014"><string-name><surname>Yin</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name><surname>Ren</surname><given-names>Q</given-names></string-name>, <string-name><surname>Su</surname><given-names>X</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Z</given-names></string-name>. <article-title>Prevalence and risk factors of diabetic retinopathy in diabetic patients: a community based cross‐sectional study</article-title>. <source>Medicine</source>. <year>2020</year>;<volume>99</volume>:<elocation-id>e19236</elocation-id>.<pub-id pub-id-type="pmid">32118727</pub-id></mixed-citation>
              </ref>
              <ref id="dme15032-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0015"><string-name><surname>Davis</surname><given-names>TME</given-names></string-name>, <string-name><surname>Bruce</surname><given-names>DG</given-names></string-name>, <string-name><surname>Davis</surname><given-names>WA</given-names></string-name>. <article-title>Cohort profile: the Fremantle diabetes study</article-title>. <source>Int J Epidemiol</source>. <year>2012</year>;<volume>42</volume>:<fpage>412</fpage>‐<lpage>421</lpage>.<pub-id pub-id-type="pmid">22544845</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0016"><string-name><surname>Drinkwater</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Davis</surname><given-names>TME</given-names></string-name>, <string-name><surname>Hellbusch</surname><given-names>V</given-names></string-name>, <string-name><surname>Turner</surname><given-names>AW</given-names></string-name>, <string-name><surname>Bruce</surname><given-names>DG</given-names></string-name>, <string-name><surname>Davis</surname><given-names>WA</given-names></string-name>. <article-title>Retinopathy predicts stroke but not myocardial infarction in type 2 diabetes: the Fremantle diabetes study phase II</article-title>. <source>Cardiovascular Diabetol</source>. <year>2020</year>;<volume>19</volume>:<fpage>43</fpage>.</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0017"><string-name><surname>Drinkwater</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Davis</surname><given-names>WA</given-names></string-name>, <string-name><surname>Turner</surname><given-names>AW</given-names></string-name>, <string-name><surname>McAullay</surname><given-names>D</given-names></string-name>, <string-name><surname>Davis</surname><given-names>TM</given-names></string-name>. <article-title>Differences in retinopathy prevalence and progression between Anglo‐Celt and aboriginal Australians: the Fremantle diabetes study phase II</article-title>. <source>Intern Med J</source>. <year>2022</year>;<volume>52</volume>(<issue>4</issue>):<fpage>590</fpage>‐<lpage>598</lpage>.<pub-id pub-id-type="pmid">33040394</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0018"><string-name><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name><surname>Fernandez‐Loaiza</surname><given-names>P</given-names></string-name>, <string-name><surname>Sauma</surname><given-names>J</given-names></string-name>, <string-name><surname>Hernandez‐Bogantes</surname><given-names>E</given-names></string-name>, <string-name><surname>Masis</surname><given-names>M</given-names></string-name>. <article-title>Classification of diabetic retinopathy and diabetic macular edema</article-title>. <source>World J Diabetes</source>. <year>2013</year>;<volume>4</volume>:<fpage>290</fpage>‐<lpage>294</lpage>.<pub-id pub-id-type="pmid">24379919</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0019"><string-name><surname>Jones</surname><given-names>BL</given-names></string-name>, <string-name><surname>Nagin</surname><given-names>DS</given-names></string-name>. <article-title>A note on a Stata plugin for estimating group‐based trajectory models</article-title>. <source>Sociol Methods Res</source>. <year>2013</year>;<volume>42</volume>:<fpage>608</fpage>‐<lpage>613</lpage>.</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0020"><string-name><surname>Nagin</surname><given-names>DS</given-names></string-name>, <string-name><surname>Odgers</surname><given-names>CL</given-names></string-name>. <article-title>Group‐based trajectory modeling in clinical research</article-title>. <source>Annu Rev Clin Psychol</source>. <year>2010</year>;<volume>6</volume>:<fpage>109</fpage>‐<lpage>138</lpage>.<pub-id pub-id-type="pmid">20192788</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0021"><string-name><surname>Matuszewski</surname><given-names>W</given-names></string-name>, <string-name><surname>Baranowska‐Jurkun</surname><given-names>A</given-names></string-name>, <string-name><surname>Stefanowicz‐Rutkowska</surname><given-names>MM</given-names></string-name>, <string-name><surname>Modzelewski</surname><given-names>R</given-names></string-name>, <string-name><surname>Pieczyński</surname><given-names>J</given-names></string-name>, <string-name><surname>Bandurska‐Stankiewicz</surname><given-names>E</given-names></string-name>. <article-title>Prevalence of diabetic retinopathy in type 1 and type 2 diabetes mellitus patients in north‐East Poland</article-title>. <source>Medicina (Kaunas)</source>. <year>2020</year>;<volume>56</volume>:<fpage>164</fpage>.<pub-id pub-id-type="pmid">32268561</pub-id></mixed-citation>
              </ref>
              <ref id="dme15032-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0022"><string-name><surname>Shah</surname><given-names>S</given-names></string-name>, <string-name><surname>Feher</surname><given-names>M</given-names></string-name>, <string-name><surname>McGovern</surname><given-names>A</given-names></string-name>, et al. <article-title>Diabetic retinopathy in newly diagnosed type 2 diabetes mellitus: prevalence and predictors of progression; a national primary network study</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2021</year>;<volume>175</volume>:<elocation-id>108776</elocation-id>.<pub-id pub-id-type="pmid">33753173</pub-id></mixed-citation>
              </ref>
              <ref id="dme15032-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0023"><string-name><surname>Alghamdi</surname><given-names>SA</given-names></string-name>, <string-name><surname>Tourkmani</surname><given-names>AM</given-names></string-name>, <string-name><surname>Alharbi</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Rsheed</surname><given-names>AB</given-names></string-name>, <string-name><surname>Almadani</surname><given-names>WH</given-names></string-name>. <article-title>Prevalence of retinopathy and associated risk factors among high‐ and low‐risk patients with type 2 diabetes mellitus</article-title>. <source>Saudi Med J</source>. <year>2021</year>;<volume>42</volume>:<fpage>693</fpage>‐<lpage>697</lpage>.<pub-id pub-id-type="pmid">34078734</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0024"><string-name><surname>Euswas</surname><given-names>N</given-names></string-name>, <string-name><surname>Phonnopparat</surname><given-names>N</given-names></string-name>, <string-name><surname>Morasert</surname><given-names>K</given-names></string-name>, et al. <article-title>National trends in the prevalence of diabetic retinopathy among Thai patients with type 2 diabetes and its associated factors from 2014 to 2018</article-title>. <source>PloS One</source>. <year>2021</year>;<volume>16</volume>:<elocation-id>e0245801</elocation-id>.<pub-id pub-id-type="pmid">33481907</pub-id></mixed-citation>
              </ref>
              <ref id="dme15032-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0025"><string-name><surname>Stratton</surname><given-names>IM</given-names></string-name>, <string-name><surname>Kohner</surname><given-names>EM</given-names></string-name>, <string-name><surname>Aldington</surname><given-names>SJ</given-names></string-name>, et al. <article-title>UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis</article-title>. <source>Diabetologia</source>. <year>2001</year>;<volume>44</volume>:<fpage>156</fpage>‐<lpage>163</lpage>.<pub-id pub-id-type="pmid">11270671</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0026"><string-name><surname>Klein</surname><given-names>R</given-names></string-name>, <string-name><surname>Klein</surname><given-names>BEK</given-names></string-name>, <string-name><surname>Moss</surname><given-names>SE</given-names></string-name>, <string-name><surname>Davis</surname><given-names>MD</given-names></string-name>, <string-name><surname>DeMets</surname><given-names>DL</given-names></string-name>. <article-title>The Wisconsin epidemiologic study of diabetic retinopathy: X. four‐year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more</article-title>. <source>Arch Ophthalmol</source>. <year>1989</year>;<volume>107</volume>:<fpage>244</fpage>‐<lpage>249</lpage>.<pub-id pub-id-type="pmid">2644929</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0027"><string-name><surname>Mitchell</surname><given-names>P</given-names></string-name>, <string-name><surname>Foran</surname><given-names>S</given-names></string-name>, <string-name><surname>Wong</surname><given-names>TY</given-names></string-name>, et al. <article-title>Guidelines for the management of diabetic retinopathy</article-title>. <source>Nat Health Med Res Council</source>. <year>2008</year>:<fpage>72</fpage>‐<lpage>74</lpage>.</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0028"><string-name><surname>Grauslund</surname><given-names>J</given-names></string-name>, <string-name><surname>Andersen</surname><given-names>N</given-names></string-name>, <string-name><surname>Andresen</surname><given-names>J</given-names></string-name>, et al. <article-title>Evidence‐based Danish guidelines for screening of diabetic retinopathy</article-title>. <source>Acta Ophthalmol</source>. <year>2018</year>;<volume>96</volume>:<fpage>763</fpage>‐<lpage>769</lpage>.<pub-id pub-id-type="pmid">30311394</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0029"><string-name><surname>Sharif</surname><given-names>A</given-names></string-name>, <string-name><surname>Jendle</surname><given-names>J</given-names></string-name>, <string-name><surname>Hellgren</surname><given-names>KJ</given-names></string-name>. <article-title>Screening for diabetic retinopathy with extended intervals, safe and without compromising adherence: a retrospective cohort study</article-title>. <source>Diabetes Ther</source>. <year>2021</year>;<volume>12</volume>:<fpage>223</fpage>‐<lpage>234</lpage>.<pub-id pub-id-type="pmid">33165837</pub-id>
</mixed-citation>
              </ref>
              <ref id="dme15032-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="dme15032-cit-0030"><string-name><surname>Broadbent</surname><given-names>DM</given-names></string-name>, <string-name><surname>Wang</surname><given-names>A</given-names></string-name>, <string-name><surname>Cheyne</surname><given-names>CP</given-names></string-name>, et al. <article-title>Safety and cost‐effectiveness of individualised screening for diabetic retinopathy: the ISDR open‐label, equivalence RCT</article-title>. <source>Diabetologia</source>. <year>2021</year>;<volume>64</volume>:<fpage>56</fpage>‐<lpage>69</lpage>.<pub-id pub-id-type="pmid">33146763</pub-id>
</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
